GridAI Technologies Corp. (GRDX): Nasdaq/NYSE listing notice — Entero Therapeutics receives Nasdaq deficiency notice for stockholders' equity shortfall

GridAI Technologies Corp.

Stockholders' equity of ($3,876,738) as of Dec 31, 2024, well below Nasdaq's $2.5M minimum.
Company also failed alternative compliance standards for market value or net income.
Must submit compliance plan by May 26, 2025; Nasdaq may grant extension to Oct 8, 2025.
Company intends to submit a plan, but no assurance of acceptance or regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

GridAI Technologies Corp. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 11, 2025, Entero Therapeutics, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of ($3,876,738) as reported in the Company’s Annual Report on Form 10-K for the period ended December 31, 2024 was below the required minimum of $2.5 million, and because, as of April 10, 2025 the C

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

GridAI Technologies Corp. filing history →

Source: SEC EDGAR

accession 0001104659-25-034689

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.